Achievement of Treat-to-Target Thresholds With Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE. J of Skin 2025, 9 (6), s650. https://doi.org/10.25251/8xwzce61.